AstraZeneca Plc, the U.K. drugmaker that resisted a Pfizer Inc. takeover attempt, is building up its respiratory business by buying the rights to Almirall SA’s lung medicines for $875 million.
AstraZeneca will pay as much as $1.22 billion more if the drugs meet development and sales goals, the London-based company said in a statement today. Almirall, based in Barcelona, also will transfer its Sofotec inhalation device unit to AstraZeneca.